We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Humoral Immunity After COVID-19 Vaccination in Chronic Lymphocytic Leukemia and Other Indolent Lymphomas: A Single-Center Observational Study.
- Authors
Doukas, Peter G; Pierre, Frederique St.; Karmali, Reem; Mi, Xinlei; Boyer, Jennifer; Nieves, Mariana; Ison, Michael G; Winter, Jane N; Gordon, Leo I; Ma, Shuo
- Abstract
Background Chronic lymphocytic leukemia (CLL) and other non-Hodgkin's lymphomas (NHLs) lead to broad immunosuppression, conferring a greater risk for morbidity and mortality from SARS-CoV-2. Our study analyzed antibody (Ab) seropositivity from SARS-CoV-2 vaccination in patients with these cancers. Methods In the final analysis, 240 patients were involved, and seropositivity was defined as a positive total or spike protein Ab. Results Seropositivity was 50% in CLL, 68% in WM, and 70% in the remaining NHLs. Moderna vaccination led to higher seropositivity compared to Pfizer vaccination across all cancers (64% vs. 49%; P =.022) and specifically CLL patients (59% vs. 43%; P =.029). This difference was not explainable by differences in treatment status or prior anti-CD20 monoclonal Ab therapy. In CLL patients, current or prior cancer therapy led to lower seropositivity compared to treatment-naïve patients (36% vs. 68%; P =.000019). CLL patients treated with Bruton's tyrosine kinase (BTK) inhibitors had better seropositivity after receiving the Moderna vaccination compared to Pfizer (50% vs. 23%; P =.015). Across all cancers, anti-CD20 agents within 1 year led to a lower Ab response compared to greater than one year (13% vs. 40%; P =.022), a difference which persisted after booster vaccination. Conclusion Antibody response is lower in patients with indolent lymphomas compared to the general population. Lower Ab seropositivity was found in patients with a history of anti-leukemic agent therapy or those immunized with Pfizer vaccine. This data suggests that Moderna vaccination may confer a greater degree of immunity against SARS-CoV-2 in patients with indolent lymphomas.
- Subjects
THERAPEUTIC use of monoclonal antibodies; CHRONIC lymphocytic leukemia; IMMUNIZATION; SCIENTIFIC observation; COVID-19; COVID-19 vaccines; CORONAVIRUS spike protein; ANTIBODY formation; CANCER patients; PROTEIN-tyrosine kinase inhibitors; DESCRIPTIVE statistics; NON-Hodgkin's lymphoma
- Publication
Oncologist, 2023, Vol 28, Issue 10, pe930
- ISSN
1083-7159
- Publication type
Article
- DOI
10.1093/oncolo/oyad121